The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Virani Shafique since 2022.
This trader's CIK number is 1856081.
At the time of last reporting, Virani Shafique was the Chief Business Officer of Recursion Pharmaceuticals, Inc.. (stock ticker symbol RXRX).
Also see all insider trading activities at Recursion Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | RXRX | 0 | $0 | 242,119 | $2,515,038 | 197,486 | $438,418 |
| 2022 | RXRX | 0 | $0 | 90,000 | $1,095,419 | 55,000 | $122,100 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-12-15 | RXRX | Sale | 18,000 | 9.60 | 172,800 |
| 2023-12-15 | RXRX | Option Ex | 18,000 | 2.22 | 39,960 |
| 2023-11-15 | RXRX | Option Ex | 18,000 | 2.22 | 39,960 |
| 2023-11-15 | RXRX | Sale | 18,000 | 6.51 | 117,180 |
| 2023-10-16 | RXRX | Option Ex | 18,000 | 2.22 | 39,960 |
| 2023-10-16 | RXRX | Sale | 18,000 | 6.30 | 113,400 |
| 2023-09-15 | RXRX | Option Ex | 18,000 | 2.22 | 39,960 |
| 2023-09-15 | RXRX | Sale | 18,000 | 8.66 | 155,880 |
| 2023-08-15 | RXRX | Sale | 18,000 | 9.25 | 166,500 |
| 2023-08-15 | RXRX | Option Ex | 18,000 | 2.22 | 39,960 |
| 2023-07-25 | RXRX | Option Ex | 20,000 | 2.22 | 44,400 |
| 2023-07-26 | RXRX | Option Ex | 20,000 | 2.22 | 44,400 |
| 2023-07-25 | RXRX | Sale | 20,000 | 14.30 | 286,000 |
| 2023-07-26 | RXRX | Sale | 20,000 | 14.41 | 288,200 |
| 2023-07-17 | RXRX | Option Ex | 30,000 | 2.22 | 66,600 |
| 2023-07-18 | RXRX | Option Ex | 30,000 | 2.22 | 66,600 |
| 2023-07-17 | RXRX | Sale | 30,000 | 11.72 | 351,600 |
| 2023-07-18 | RXRX | Sale | 30,000 | 13.74 | 412,200 |
| 2023-06-01 | RXRX | Sale | 25,000 | 8.58 | 214,500 |
| 2023-06-02 | RXRX | Sale | 17,865 | 8.93 | 159,534 |
| 2023-02-15 | RXRX | Option Ex | 7,486 | 2.22 | 16,618 |
| 2023-02-15 | RXRX | Sale | 7,486 | 8.33 | 62,358 |
| 2023-02-16 | RXRX | Sale | 1,768 | 8.42 | 14,886 |
| 2022-12-15 | RXRX | Option Ex | 5,000 | 2.22 | 11,100 |
| 2022-12-15 | RXRX | Sale | 10,000 | 8.85 | 88,530 |
| 2022-11-15 | RXRX | Option Ex | 5,000 | 2.22 | 11,100 |
| 2022-11-15 | RXRX | Sale | 10,000 | 12.31 | 123,080 |
| 2022-11-15 | RXRX | Option Ex | 5,000 | 2.22 | 11,100 |
| 2022-11-15 | RXRX | Sale | 10,000 | 12.31 | 123,080 |
| 2022-10-14 | RXRX | Option Ex | 5,000 | 2.22 | 11,100 |
| 2022-10-14 | RXRX | Sale | 10,000 | 10.92 | 109,179 |
| 2022-09-15 | RXRX | Sale | 10,000 | 13.65 | 136,550 |
| 2022-09-15 | RXRX | Option Ex | 5,000 | 2.22 | 11,100 |
| 2022-09-15 | RXRX | Sale | 10,000 | 13.65 | 136,550 |
| 2022-09-15 | RXRX | Option Ex | 5,000 | 2.22 | 11,100 |
| 2022-08-16 | RXRX | Option Ex | 25,000 | 2.22 | 55,500 |
| 2022-08-16 | RXRX | Sale | 30,000 | 12.62 | 378,450 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Virani Shafique (Chief Business Officer of Recursion Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.